4D Molecular Therapeutics secured the return of Berkeley Catalyst Fund for a series C round that follows plans for a $100m IPO announced in September 2019.

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Based on research from academic schools including Princeton, Chicago and Alabama at Birmingham, the oncolytic viral therapy developer has now received more than $80m to date.

The educational game portal, a spinout of Norwegian University of Science and Technology, pulled in $28m as investors also bought $62m of secondary shares.

GV, a corporate venturing subsidiary of internet and technology group Alphabet, has led a $63m series A2 round for Verve Therapeutics, a US-based developer of genomic heart disease drugs.

University of Cambridge stem cell differentiation spinout Bit Bio secured $41.5m from investors including Arch Venture Partners to boost its overall funding to $50m.

The Aalto University and VTT quantum computer spinout has lined up a potential series A round with an initial $16.9m contribution from EIC Accelerator.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Based on research at University of Adelaide, Royal Adelaide Hospital and Johns Hopkins's Hospital, Glyscend is working on a pill to treat type 2 diabetes.